- Home
- LVTX vs COCH Comparison
LVTX vs COCH Comparison
Compare LVTX & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- COCH
- Stock Information
- Founded
- LVTX 2016
- COCH 1995
- Country
- LVTX Netherlands
- COCH United States
- Employees
- LVTX N/A
- COCH N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- COCH Blank Checks
- Sector
- LVTX Health Care
- COCH Finance
- Exchange
- LVTX Nasdaq
- COCH Nasdaq
- Market Cap
- LVTX 33.9M
- COCH 31.6M
- IPO Year
- LVTX 2021
- COCH N/A
- Fundamental
- Price
- LVTX $1.31
- COCH $1.40
- Analyst Decision
- LVTX Hold
- COCH Strong Buy
- Analyst Count
- LVTX 3
- COCH 2
- Target Price
- LVTX $1.75
- COCH $9.25
- AVG Volume (30 Days)
- LVTX 39.1K
- COCH 27.5K
- Earning Date
- LVTX 08-19-2025
- COCH 08-11-2025
- Dividend Yield
- LVTX N/A
- COCH N/A
- EPS Growth
- LVTX N/A
- COCH N/A
- EPS
- LVTX N/A
- COCH N/A
- Revenue
- LVTX $4,990,000.00
- COCH $212,000.00
- Revenue This Year
- LVTX N/A
- COCH $8.04
- Revenue Next Year
- LVTX N/A
- COCH $15.39
- P/E Ratio
- LVTX N/A
- COCH N/A
- Revenue Growth
- LVTX N/A
- COCH N/A
- 52 Week Low
- LVTX $0.85
- COCH $1.21
- 52 Week High
- LVTX $2.39
- COCH $3.99
- Technical
- Relative Strength Index (RSI)
- LVTX 51.02
- COCH 42.45
- Support Level
- LVTX $1.28
- COCH $1.35
- Resistance Level
- LVTX $1.40
- COCH $1.53
- Average True Range (ATR)
- LVTX 0.05
- COCH 0.11
- MACD
- LVTX -0.00
- COCH -0.02
- Stochastic Oscillator
- LVTX 52.63
- COCH 15.62
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.